Recommended
Recommended
Recent Quotes
My Watchlist
Indicators
Local Stocks
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cyteir Therapeutics Inc (NQ: CYT )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 3.070 (100)
Ask (Size) 3.140 (105)
Prev. Close 3.020
Today's Range N/A - N/A
52wk Range 2.970 - 3.190
Shares Outstanding 71,281,616
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cyteir Announces Timeline for Voluntarily Delisting from Nasdaq
From Cyteir Therapeutics
Via Business Wire
Ongoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety Profile
From Cyteir Therapeutics
Via Business Wire

Performance

More News

Read More
Nasdaq Jumps 200 Points; Baudax Bio Shares Spike Higher
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Cyteir Therapeutics (NASDAQ: CYT) to Dissolve After Discontinuing Development of CYT-0851
Via Spotlight Growth
Why Cineverse Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Crude Oil Rises Over 1%; Fed's Preferred Inflation Gauge Slows In May
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Cyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and Dissolution
From Cyteir Therapeutics
Via Business Wire
Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Clinical Activity and Generally Well Tolerated Safety Profile
From Cyteir Therapeutics
Via Business Wire
Cyteir Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights
From Cyteir Therapeutics, Inc.
Via Business Wire
Cyteir Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
From Cyteir Therapeutics
Via Business Wire
Cyteir Therapeutics Promotes David Gaiero to Chief Financial Officer
From Cyteir Therapeutics
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023
Via Benzinga
Cyteir Therapeutics Announces Prioritization of CYT-0851 Development and Extended Cash Runway
From Cyteir Therapeutics
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 20, 2023
Via Benzinga
Cyteir Therapeutics Reports Third Quarter 2022 Financial Results and Operational Highlights
From Cyteir Therapeutics
Via Business Wire
Cyteir Therapeutics Presents Poster on the Identification of Mechanism of Action of CYT-0851 at the 34th Annual EORTC-NCI-AACR Symposium
From Cyteir Therapeutics
Via Business Wire
5 Value Stocks In The Healthcare Sector
Via Benzinga
Cyteir Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
From Cyteir Therapeutics
Via Business Wire
Cyteir Therapeutics Reports Second Quarter 2022 Financial Results and Operational Highlights
From Cyteir Therapeutics
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
Via Benzinga
Cyteir Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference
From Cyteir Therapeutics
Via Business Wire
Why This Biotechnology Surged More Than 60%; Here Are 67 Biggest Movers From Yesterday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.